Metopirone

Metyrapone, the active ingredient in Metopirone, is a steroidogenesis inhibitor presented as an oral tablet for oral use. It reduces cortisol synthesis and is employed in diagnostic testing of adrenal function as well as in the therapeutic management of Cushing's syndrome and adrenal insufficiency. GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopirone acts on adrenal steroidogenesis and is used in several endocrine indications.

Diagnostic testing of adrenal function: facilitates assessment of cortisol production during dynamic testing. Treatment of Cushing's syndrome: helps lower excessive cortisol levels in patients with endogenous hypercortisolism. Management of adrenal insufficiency: used adjunctively to support cortisol synthesis when endogenous production is inadequate.

Metyrapone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or vomiting - Headache - Dizziness or light‑headedness - Fatigue or weakness - Mild abdominal discomfort

Serious or Rare Side Effects: - Hypertension or severe blood pressure fluctuations - Acute adrenal crisis in susceptible individuals - Severe allergic reactions (anaphylaxis, rash, swelling) - Electrolyte disturbances, especially hyponatremia or hyperkalemia - Hepatic enzyme elevations

Before initiating Metopirone, consider the following safety measures.

Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Breastfeeding: avoid unless clearly needed, as the drug may pass into milk. Cardiovascular disease: monitor blood pressure closely due to possible hypertension. Adrenal insufficiency: ensure adequate glucocorticoid replacement to prevent crisis. Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Metyrapone can affect the activity of several concomitant medicines.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce efficacy. - Drugs that also suppress cortisol (e.g., ketoconazole) increasing risk of adrenal insufficiency.

Moderate Interactions (Monitor Closely): - Antihypertensives: blood pressure may fluctuate. - Anticoagulants: cortisol changes can alter coagulation parameters. - Oral contraceptives: hormonal balance may be affected.